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Pharmaceuticals: Getting Better Value for 
Money 
 
Paul K. Gorecki, Anne Nolan, Aoife Brick and Seán Lyons1 
 
The Irish health-care system is under severe budgetary pressure. Pharmaceutical 
expenditure is no exception. During the 2000s Ireland experienced one of the 
highest annual growth rates in pharmaceutical expenditure of any OECD country. 
In 2009 Ireland spent more on pharmaceuticals per capita than any other OECD 
country (with the exception of the US, Canada and Greece). 
 
The onset of the financial crisis has seen a number of austerity budgets, which 
will continue until at least 2015. Public expenditure is being tightened. 
Households, whose incomes are being squeezed, are likely to be asked to make 
greater out-of-pocket contributions towards pharmaceuticals. Budget 2012, for 
example, raised the monthly threshold for the Drug Payment Scheme by €12 to 
€132 and retained the 50c charge per prescription item for medical card patients, 
which was introduced in October 2012. 
 
Nevertheless, significant progress has been made in recent years in reducing the 
cost of delivery of pharmaceuticals in Ireland, both to the Health Services 
Executive (HSE) and the cash paying customer. For example, wholesale margins 
have been reduced and pharmacy mark-ups have declined, at least for 
pharmaceuticals paid for by the state. However, more can and needs to be done 
to take these reforms forward. 
 
The Health Service Executive asked the ESRI to undertake a study of the 
pharmaceutical delivery system with a view to ensuring better value for money, 
while assuring security of supply. The report, Delivery of Pharmaceuticals in 
Ireland. Getting a Bigger Bang for the Buck†, made a wide ranging set of 
recommendations and suggestions on how Ireland can obtain better value for 
money in its pharmaceutical expenditure. These recommendations covered all 
stages in the delivery system from the manufacturer through to the pharmacist 
and the prescriber. In this Research Bulletin some of the major recommendations 
are highlighted. 
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The expiry on 1 March 2012 of the agreement between the state and the Irish 
Pharmaceutical Healthcare Association, which represents the international 
research-based pharmaceutical firms, provides an opportunity to set lower ex-
factory prices for new pharmaceuticals. The ex-factory price is that charged by 
the manufacturer at the factory gate, while new pharmaceuticals are those 
recently introduced pharmaceuticals subject to patent protection with no direct 
competition. The ex-factory price of new pharmaceuticals is currently set as the 
average across a basket of nine EU Member States: Belgium, Denmark, France, 
Germany, Netherlands, Spain, the UK, Finland, and Austria. If instead of the 
average the lowest price was used, then the ex-factory would be reduced by 
between 20 to 25 per cent. Other Member States typically use the lowest rather 
than the average price. 
 
The Department of Health is to introduce the Health (Pricing and Supply of 
Medical Goods) Bill later in 2012 which is designed to encourage generic 
substitution and reference pricing. Generic substitution allows the pharmacist to 
select a different, usually lower priced, product from that prescribed. A reference 
price sets for brands of the same pharmaceutical which have been certified as 
interchangeable pharmaceutical products, the ex-factory price for that particular 
group. For high volume interchangeable pharmaceutical products the reference 
price should be set by competitive tendering. The winner of the tender (i.e. the 
lowest priced bid) would set the reference price and supply the market. If the 
prescriber decides to select a different – usually the higher-priced originators –
brand for the patient, then the prescriber would be required to: (i) specify the 
medical reason for their decision; and (ii) write in their own hand 'no substitution' 
on the prescription. This should provide valuable feedback on the 
implementation of generic substitution and reference pricing. 
 
The pharmacy market is marked by a lack of information available to patients on 
not only pharmaceutical prices, mark-ups and dispensing fees, but also the 
services supplied by pharmacists. These services have been expanding with the 
administration of the seasonal influenza vaccine and the dispensing of emergency 
hormonal contraception. In other professions such as dentistry and medicine in 
Ireland, as well as pharmacy in other jurisdictions, patients are provided with 
information that assists them in deciding which provider to choose. Despite the 
marked reluctance of the industry regulator, the Pharmaceutical Society of 
Ireland, the same should apply for pharmacy in Ireland. Dispensing fees, services 
offered and mark-ups should be posted in pharmacies, and pharmacists should 
have the option of using media to disseminate such information. New forms of 
retailing such as the internet should – under the appropriate regulatory 
conditions – be considered by the HSE, perhaps on a trial basis. The result should 
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be a more competitive, efficient and vibrant pharmacy sector that is more 
responsive to patient preferences and needs. 
 
The prescriber, typically the family doctor, acts on the patient's behalf in making 
decisions concerning the appropriate course of treatment in addressing the 
patient's condition. This may involve selection of a pharmaceutical. In writing a 
prescription the international non-proprietary name (INN) – atorvastatin, rather 
than Lipitor, fluoxetine rather than Prozac – should be used by the prescriber. The 
INN identifies the pharmaceutical substance or active pharmaceutical ingredient. 
Each INN is a unique name that is globally recognised and is public property. A 
non-proprietary name is also known as a generic name. INN prescribing is safer as 
it reduces the potential for confusion when prescribing or when seeking to 
identify a pharmaceutical that a patient has been taking. There are likely to be 
exceptions to INN prescribing such as that referred to above in the discussion of 
no-substitution prescriptions. The evidence suggests low levels of INN prescribing 
in Ireland. 
 
In designing ways of achieving better value for money, the recommendations are 
based on evolution, rather than revolution. In part this approach has been driven 
by the observation that variation within health care systems is much greater than 
between them. Thus, by reforming the current model of pharmaceutical delivery, 
better value for money can be realised, while at the same time the costs and 
unintended consequences of large changes can be prevented. This minimises the 
chances that there will be an adverse impact on security of supply. 
 
The recommendations contained in the ESRI report commissioned by the HSE are 
designed to ensure that taxpayers get better value for money from the €1.9 
billion public pharmaceutical budget, but also that the cash paying patients 
benefits too. They are also designed to ensure that patients, irrespective of 
whether or not the state pays for the pharmaceutical, receive safe and effective 
pharmaceuticals without interruption to supply. 
 
†Paul K. Gorecki, Anne Nolan, Aoife Brick and Seán Lyons, Delivery of 
Pharmaceuticals in Ireland. Getting a Bigger Bang for the Buck. Research Series 
Number 24, Dublin: ESRI. January 2012. 
